Bifogade filer
NET ASSET VALUE – 31 August 2024
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Flerie AB via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Mid Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2024-09-03 08:00:00
On the 31 August 2024 Flerie AB's Net Asset Value (NAV) was SEK 4,360 million and NAV per share was SEK 55.85.
| Allocation of NAV | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV | |
| Product Development | |||||
| Prokarium | 42% | 473 | 6.06 | 10.9% | |
| Xspray Pharma | 18% | 303 | 3.88 | 7.0% | |
| Xintela | 56% | 205 | 2.63 | 4.7% | |
| Empros Pharma | 79% | 204 | 2.62 | 4.7% | |
| KAHR Medical | 31% | 193 | 2.47 | 4.4% | |
| Atrogi | 37% | 176 | 2.25 | 4.0% | |
| Lipum | 57% | 148 | 1.90 | 3.4% | |
| Microbiotica | 11% | 135 | 1.73 | 3.1% | |
| Mendus | 24% | 103 | 1.32 | 2.4% | |
| Geneos Therapeutics | 12% | 98 | 1.26 | 2.3% | |
| Toleranzia | 58% | 58 | 0.75 | 1.3% | |
| EpiEndo Pharmaceuticals | 9% | 56 | 0.72 | 1.3% | |
| Synerkine Pharma | 43% | 52 | 0.67 | 1.2% | |
| AnaCardio | 19% | 52 | 0.66 | 1.2% | |
| Egetis Therapeutics | 2% | 42 | 0.53 | 1.0% | |
| Buzzard Pharmaceuticals | 14% | 29 | 0.37 | 0.7% | |
| Vitara Biomedical | 5% | 27 | 0.35 | 0.6% | |
| Sixera Pharma | 23% | 26 | 0.33 | 0.6% | |
| Alder Therapeutics | 21% | 17 | 0.22 | 0.4% | |
| Amarna Therapeutics | 60% | 11 | 0.15 | 0.3% | |
| Strike Pharma | 16% | 9 | 0.11 | 0.2% | |
| Total | 2,419 | 30.98 | 55.5% | ||
| Commercial Growth | |||||
| NorthX Biologics | 92% | 189 | 2.42 | 4.3% | |
| Symcel | 31% | 169 | 2.16 | 3.9% | |
| A3P Biomedical | 8% | 75 | 0.96 | 1.7% | |
| Chromafora | 31% | 73 | 0.93 | 1.7% | |
| Provell Pharmaceuticals | 72% | 68 | 0.87 | 1.6% | |
| Nanologica | 39% | 42 | 0.54 | 1.0% | |
| Frontier Biosolutions | 2% | 19 | 0.24 | 0.4% | |
| Bohus Biotech | 45% | 17 | 0.21 | 0.4% | |
| Total | 651 | 8.34 | 14.9% | ||
| Limited Partnerships, total | 87 | 1.11 | 2.0% | ||
| Assets related to portfolio companies | 398 | 5.10 | 9.1% | ||
| Other assets and liabilities | 805 | 10.32 | 18.5% | ||
| NAV | 4 360 | 55.85 | 100.0% | ||
| * indirect shares in Provell Pharmaceuticals | |||||